All In Biotech

NDA 020220 · Bayer Hlthcare

Ultravist 150

Iopromide · Injection · Radiographic Contrast Agent

Novel

Last checked: Nov 20, 2026Latest source record: Jun 15, 2023 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

1995

May 10, 1995

Approved uses

4

Original approval plus efficacy supplements

Registered trials

8

1 Phase 3, 0 recruiting

FAERS reports

4,182

3,709 serious, 336 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

Boxed warning

WARNING: NOT FOR INTRATHECAL USE WARNING: NOT FOR INTRATHECAL USE See full prescribing information for complete boxed warning. Intrathecal administration, even if inadvertent, may cause death, convulsions, cerebral hemorrhage, coma, paralysis, arachnoiditis, acute renal failure, cardiac arrest, seizures, rhabdomyolysis, hyperthermia, and brain edema. ULTRAVIST is not approved for intrathecal use. (5.1)

What it is approved for

From the label in effect Mar 2, 2026.

ULTRAVIST ® Injection is an iodinated contrast agent indicated for: ULTRAVIST is a radiographic contrast agent indicated for: Intra-Arterial Procedures † • Cerebral arteriography and peripheral arteriography in adults ( 1.1 ) • Coronary arteriography and left ventriculography, visceral angiography, and aortography in adults ( 1.1 ) • Radiographic evaluation of cardiac chambers and related arteries in pediatric patients aged 2 years and older ( 1.1 ) Intravenous Procedures † • Excretory urography in adults and pediatric patients aged 2 years and older ( 1.2 ) • Contrast computed tomography (CT) of head and body in adults and pediatric patients aged 2 years and older ( 1.2 ) • Contrast mammography in adults as an adjunct following mammography and/or ultrasound ( 1.2 ) † Specific concentrations and presentations are recommended for each type of imaging procedure. ( 2.2 , 2.3 , 2.4 ) 1.1 Intra-Arterial Procedures* ULTRAVIST is indicated for: • Cerebral arteriography and peripheral arteriography in adults • Coronary arteriography and left ventriculography, visceral angiography, and aortography in adults • Radiographic evaluation of cardiac chambers and related arteries in pediatric patients aged 2 years and older 1.2 Intravenous Procedures* ULTRAVIST is indicated for: • Excretory urography in adults and pediatric patients aged 2 years and older • Contrast Computed Tomography (CT) of the head and body (intrathoracic, intra-abdominal, and retroperitoneal regions) for the evaluation of neoplastic and non-neoplastic lesions in adults and pediatric patients aged 2 years and older • Contrast mammography to visualize known or suspected lesions of the breast in adults, as an adjunct following mammography and/or ultrasound † Specific concentrations and presentations of ULTRAVIST are...

Mechanism: Intravascular injection of iopromide opacifies those vessels where the contrast agent is present, permitting radiographic visualization of the internal structures through attenuation of photons. In imaging of the body, iodinated contrast agents diffuse from the vessels into the extravascular space. In normal brain with an intact blood-brain barrier, contrast does not diffuse into the extravascular space. In patients with a disrupted blood-brain barrier, contrast agent accumulates in the extravascular space in the region of disruption.

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • May 25, 2023 Supplement 54 · Efficacy LetterLabel
  • Dec 30, 2009 Supplement 33 · Efficacy LabelLetter
  • Jul 23, 1997 Supplement 2 · Efficacy
  • May 10, 1995 Original approval · Type 1 - New Molecular Entity
5 products under this application
  • ULTRAVIST 150 · IOPROMIDE 31.2% · INJECTABLE, INJECTION · Discontinued
  • ULTRAVIST 300 · IOPROMIDE 62.3% · INJECTABLE, INJECTION · Prescription
  • ULTRAVIST 300 IN PLASTIC CONTAINER · IOPROMIDE 62.3% · INJECTABLE, INJECTION · Discontinued
  • ULTRAVIST 240 · IOPROMIDE 49.9% · INJECTABLE, INJECTION · Discontinued
  • ULTRAVIST 370 · IOPROMIDE 76.9% · INJECTABLE, INJECTION · Prescription

Clinical trials

Interventional ClinicalTrials.gov studies with "Iopromide" as an intervention, any sponsor and status, largest first.

All 8 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • dyspnoea621
  • urticaria545
  • pruritus481
  • erythema394
  • anaphylactic shock389
  • blood pressure decreased376
  • nausea320
  • vomiting293
  • loss of consciousness255
  • oxygen saturation decreased248
  • dizziness230
  • rash228

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
20041
20057
20061
20073
200813
200929
201015
201117
2012103
2013194
2014208
2015231
2016239
2017203
2018229
2019198
2020282
2021176
2022279
2023413
2024493
2025456
2026392

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 161 on PubMed

Sponsor: Bayer · Also marketed as Ultravist 300, Ultravist 300 In Plastic Container, Ultravist 240, Ultravist 370

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.